Phase 2 trials, explained

690 reference articles. Public record; not medical advice.

• 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC · NCT07043270
• 3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial · NCT05674396
• 5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC · NCT05317000
• 5-Day Preoperative Radiation for Soft Tissue Sarcoma · NCT06087861
• 5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer · NCT06887218
• A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer · NCT07078604
• A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014) · NCT07209111
• A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012) · NCT06961006
• A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) · NCT06890884
• A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study · NCT04641247
• A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial · NCT06069726
• A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer · NCT05242965
• A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer · NCT05604560
• A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas · NCT07003542
• A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer · NCT07102381
• A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer · NCT07133425
• A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC) · NCT05035836
• A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia. · NCT06566742
• A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma · NCT05548296
• A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL · NCT06854653
• A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment · NCT05708352
• A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer · NCT07659795
• A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer · NCT07644559
• A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex) · NCT06514794
• A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors · NCT06695845
• A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy) · NCT06561074
• A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer · NCT07005154
• A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab · NCT02621021
• A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers · NCT06805617
• A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma · NCT06563505
• A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL) · NCT07508995
• A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE) · NCT07193550
• A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA · NCT06698822
• A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer · NCT06710288
• A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) · NCT06907615
• A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma · NCT02491099
• A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies · NCT06668584
• A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy · NCT05361798
• A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma · NCT06043323
• A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy · NCT05464719
• A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement · NCT06728410
• A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes · NCT06229912
• A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB) · NCT05673928
• A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma · NCT07085338
• A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL · NCT05615636
• A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors · NCT06248515
• A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma · NCT06942442
• A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer · NCT05563766
• A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study · NCT06630091
• A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases · NCT06764940
• A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer · NCT06992258
• A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) · NCT06661915
• A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC) · NCT07188896
• A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs) · NCT06004336
• A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss · NCT05593497
• A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma · NCT05967182
• A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment · NCT07179315
• A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC · NCT07807163
• A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer · NCT07603856
• A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes · NCT07748208
• A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT · NCT04684368
• A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma · NCT06057948
• A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer · NCT06095505
• A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) · NCT06667076
• A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer · NCT05498428
• A Study of Avutometinib and Defactinib in People With Thyroid Cancer · NCT06007924
• A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer · NCT06394804
• A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma · NCT06213311
• A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer · NCT05128825
• A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01) · NCT07700758
• A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy · NCT07227636
• A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma · NCT06843434
• A Study of Cadonilimab Combined With Chemotherapy in People With Gastric or Gastroesophageal Junction Cancer · NCT07631000
• A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT · NCT04322318
• A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS) · NCT06083922
• A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 · NCT04879329
• A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies · NCT07271667
• A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer · NCT05726292
• A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) · NCT06842498
• A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma · NCT06594991
• A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer · NCT07287098
• A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression · NCT07023627
• A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01) · NCT06780085
• A Study of Ivonescimab in People With Endometrial and Cervical Cancers · NCT06925724
• A Study of Ivonescimab in People With Leiomyosarcoma · NCT07516925
• A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer · NCT07832292
• A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC) · NCT06667908
• A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma · NCT07533942
• A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma · NCT07741877
• A Study of Lower Dose Radiation Therapy for People With Prostate Cancer · NCT07635238
• A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma · NCT06368817
• A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC · NCT07459634
• A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma · NCT05389293
• A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) · NCT04302025
• A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC) · NCT05851924
• A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9) · NCT06855771
• A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC · NCT07586202
• A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma · NCT07069712
• A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) · NCT07450859
• A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) · NCT07221500
• A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia · NCT07400029
• A Study of Pembrolizumab in People With Ultra-Rare Sarcomas · NCT07089992
• A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01) · NCT06731907
• A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer · NCT06123338
• A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) · NCT07231952
• A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma · NCT05929612
• A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer · NCT05838521
• A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma · NCT07123090
• A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer · NCT05570253
• A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors · NCT05985161
• A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma · NCT04661137
• A Study of Sotorasib in People With Non-Small Cell Lung Cancer · NCT06582771
• A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain · NCT06741085
• A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain · NCT05419076
• A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer · NCT06533644
• A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC · NCT06971614
• A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide · NCT06844383
• A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma · NCT04634552
• A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment · NCT07293247
• A Study of Tarlatamab for People With Prostate Cancer · NCT07111507
• A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer · NCT06038578
• A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia · NCT05955261
• A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma · NCT07428616
• A Study of ZEN003694 in People With Squamous Cell Lung Cancer · NCT05607108
• A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) · NCT06124157
• A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease · NCT07023289
• A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer · NCT07059845
• A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) · NCT06568939
• A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma · NCT07744126
• A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. · NCT06890338
• A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations · NCT05503797
• A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases · NCT04511013
• A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia · NCT07107334
• A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel · NCT07149857
• A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer · NCT06820463
• A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) · NCT07227311
• A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients · NCT06010342
• A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma · NCT07284758
• A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer · NCT07155174
• A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer · NCT06948448
• A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder · NCT07475806
• A Study to Give Treatment Inside the Eye to Treat Retinoblastoma · NCT05504291
• A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) · NCT07154290
• A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) · NCT06760819
• A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma · NCT06769698
• A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer. · NCT07235293
• A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer · NCT07054190
• A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) · NCT06064097
• A Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma · NCT07229417
• A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer · NCT06503614
• A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity · NCT06406465
• Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration · NCT04040205
• Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer · NCT04469764
• Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · NCT07237269
• Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer. · NCT05422911
• Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial · NCT04941716
• Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma · NCT04002947
• Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma · NCT03516617
• Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma · NCT04404088
• Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer · NCT06850623
• ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas · NCT06838676
• AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma · NCT05669339
• Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma · NCT07689175
• Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer · NCT06525766
• Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery · NCT07037004
• Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) · NCT06390319
• Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer · NCT06728072
• Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer · NCT07149363
• Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone · NCT06526338
• Adjuvant Quisinostat in High-Risk Uveal Melanoma · NCT06932757
• Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer · NCT03412877
• ALL Backbone in AYAs · NCT07227584
• Allo HSCT Using RIC and PTCy for Hematological Diseases · NCT05805605
• AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion · NCT04099966
• Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma · NCT05847569
• Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma · NCT07780838
• An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer · NCT06693336
• An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib · NCT05887609
• Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer · NCT04947254
• Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies · NCT04114136
• APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation · NCT04858334
• Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma · NCT06918431
• ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer · NCT07007559
• Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy · NCT06184516
• ATEMPT 2.0: Adjuvant T-DM1 vs TH · NCT04893109
• Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study · NCT05019703
• Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer · NCT05168163
• Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer · NCT05312671
• Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer · NCT04614103
• Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome · NCT03383575
• AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 · NCT06219941
• BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases · NCT07550088
• Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma · NCT05208307
• Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) · NCT04924075
• BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study · NCT05136196
• Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma · NCT04598009
• Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant · NCT04322383
• Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma · NCT06014827
• Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology · NCT06417190
• BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma · NCT07226856
• Brain Metastases in Greater Size - Hypofractionated Options Trial (BIGSHOT) · NCT07227610
• BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer · NCT06441890
• Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma · NCT04587687
• Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma · NCT04561206
• Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors · NCT05039073
• Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer · NCT06738303
• Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma · NCT04472767
• Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity · NCT01639508
• Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence · NCT05952934
• CapTemY90 for Grade 2/3 NET Liver Metastases · NCT04339036
• CAR T-cell Therapy in Patients With Renal Dysfunction · NCT05909059
• Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance · NCT04332367
• CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia · NCT07328503
• Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity and HPV-negative Oropharyngeal Squamous Cell Carcinoma · NCT06448026
• Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT Carcinoma · NCT07050186
• Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma · NCT06790602
• Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer · NCT04375384
• Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC) · NCT04926467
• Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas · NCT04623931
• Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma · NCT05001880
• Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer · NCT03161522
• Circulating Tumor DNA · NCT06923527
• Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy · NCT05770531
• Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia · NCT00412594
• CLAG-GO for Patients With Persistent, Relapsed or Refractory AML · NCT04050280
• Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders · NCT04079179
• Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia · NCT03136146
• Combination Therapy for the Treatment of Diffuse Midline Gliomas · NCT05009992
• Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma · NCT07766187
• Combined Systemic and Intraperitoneal Chemotherapy for Synchronous Gastric and/or Gastroesophageal Peritoneal Carcinomatosis · NCT07475286
• Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) · NCT05554393
• Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) · NCT07437950
• Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial) · NCT06672146
• Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial · NCT05886036
• Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment · NCT06955169
• Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV) · NCT07770100
• Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL · NCT06500273
• Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma · NCT07048457
• Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases · NCT06013423
• CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome · NCT04493164
• Cryoablation+Ipilimumab+Nivolumab in Melanoma · NCT05779423
• ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab · NCT07504796
• ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST · NCT05366816
• ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma · NCT07021989
• ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer · NCT07425054
• Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer · NCT03099356
• Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas · NCT07110246
• DALY II USA/ MB-CART2019.1 for DLBCL · NCT04792489
• Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL · NCT05289687
• Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease · NCT05907759
• DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers · NCT05882058
• Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma · NCT06940297
• DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs · NCT06176261
• DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment · NCT06075953
• Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms · NCT04282187
• Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma · NCT05960773
• Defining the Ablative Dose for Y-90 TARE · NCT07586046
• DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma · NCT04696029
• Digoxin Medulloblastoma Study · NCT06701812
• DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC · NCT06364917
• DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM) · NCT06805305
• Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma · NCT07224100
• Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial · NCT03907475
• Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas · NCT07293403
• E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers · NCT05686226
• Effects of Infusion Timing on Treatment Response in Solid Tumors · NCT07630168
• Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) · NCT04728893
• Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer · NCT06995677
• Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker · NCT07060001
• Elranatamab in R/R Multiple Myeloma · NCT06138275
• Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation · NCT03683433
• Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors · NCT06176989
• Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score · NCT02476786
• Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE) · NCT06041503
• Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy · NCT06096870
• Epco, Zanu, Ritux for R/R FL or MZL · NCT06563596
• Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma · NCT06723457
• Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma · NCT06919939
• Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma · NCT07097363
• Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma · NCT07365306
• Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial · NCT07466498
• ETHAN - ET for Male BC · NCT05501704
• EUS-RFA PANCARDINAL-1 Trial · NCT04990609
• Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL · NCT06806033
• Evaluating a Decreased Dose of Radiation Therapy to the Elective Neck for the Treatment of HPV-Related Oropharyngeal Cancer, ENLIGHT Trial · NCT07178301
• Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma · NCT07428993
• Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients · NCT07460752
• Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer · NCT03832361
• Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease · NCT06875128
• Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease · NCT06607458
• Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission · NCT06824168
• EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study Evaluating Initial Response to Systemic Therapy and Subsequent Integration of Stereotactic Radiosurgery in Patients With Low-risk Brain Metastases and Central Nervous System-active · NCT06649058
• Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma · NCT04930653
• FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial · NCT06244004
• Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet® · NCT03290534
• Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome · NCT00801489
• Fluorescence-Guided Surgical Resection for Reducing Unexpected Positive Margins in Patients With Sarcoma, SarcoSIGHT Trial · NCT07650656
• Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor · NCT05616650
• Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial · NCT06639074
• FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer · NCT07446322
• FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery · NCT06780787
• Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia · NCT03737955
• Frameless Stereotactic Radiosurgery for Intact Brain Metastases · NCT02747303
• Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC · NCT05464082
• Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy · NCT06263153
• Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC) · NCT06592599
• Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery · NCT04891289
• Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer · NCT06423326
• Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer · NCT06576115
• Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study · NCT05361720
• Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer · NCT04812366
• Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer · NCT05528133
• GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma · NCT07301268
• Glioblastoma: temozolomide with or without WSD0922-FU · NCT07708961
• Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma · NCT06252675
• GLORY: Glofit-GemOx With Liso-Cel For Lymphoma · NCT07711483
• Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy · NCT06834373
• Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) · NCT03970096
• GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer · NCT07017829
• Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis · NCT03520647
• Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Neuroblastoma · NCT07635056
• HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM · NCT06822972
• HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission · NCT07459673
• High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly · NCT06345495
• High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers · NCT05011383
• Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer · NCT06518057
• Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial · NCT06067269
• Hotspot Stereotactic Ablative Radiotherapy Versus Traditional Stereotactic Ablative Radiotherapy for the Treatment of Early-Stage Non-Small Cell Lung Cancer · NCT07718672
• Hypofractionated Radiation Therapy for Merkel Cell Carcinoma · NCT05100095
• Hypofractionated Radiochemotherapy · NCT06331468
• Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma · NCT06107738
• Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing · NCT07485647
• IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study) · NCT05401097
• IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence · NCT07495124
• IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases · NCT06092892
• ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer · NCT07452224
• Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG). · NCT07680439
• Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial · NCT07191717
• IMMUNOPLANT for Newly Diagnosed Multiple Myeloma · NCT06376526
• Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer · NCT07140679
• Immunotherapy and Nodal-Sparing Irradiation for T-Cell Induction and Unmasking of Tumor Antigenicity in the Microenvironment for Head and Neck Cancer · NCT07773987
• Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial · NCT07288034
• Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer · NCT04918186
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer · NCT01174121
• Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients · NCT04677816
• INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) · NCT02977780
• Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) · NCT04374305
• Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma · NCT07096778
• Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia · NCT03739814
• Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS) · NCT06802315
• Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma · NCT05428007
• Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes · NCT05832086
• Intralesional Chemotherapy (IC): Cisplatin + Epinephrine · NCT07392580
• Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer · NCT06787612
• Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC · NCT07405190
• Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer · NCT07094685
• Ivonescimab for the Treatment of Thymic Cancer · NCT06980077
• Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA · NCT07070466
• Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer · NCT07226544
• Ivosidenib as Post-HSCT Maintenance for AML · NCT06707493
• KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) · NCT07252739
• KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line) · NCT07406633
• L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma · NCT07228442
• L19IL2/TNF in Patients With Basal Cell Carcinoma · NCT07227870
• Lerapolturev (PVSRIPO) in GBM · NCT06177964
• Letrozole in Uterine Leiomyosarcoma · NCT05649956
• Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial · NCT07158021
• Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer · NCT05854498
• Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia · NCT03629171
• Liquid Nitrogen Spray Cryotherapy Prior to Neoadjuvant Systemic Therapy in Esophageal Adenocarcinoma · NCT07222657
• Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy · NCT04892953
• Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma · NCT05672251
• Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL) · NCT06788964
• Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma · NCT06442475
• Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease · NCT06526299
• Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma · NCT03206060
• Luminal Bladder Cancer Effective Response to Neoadjuvant Chemotherapy (LUMBER-NAC) · NCT07762586
• Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER) · NCT06228066
• Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy · NCT04082520
• Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer · NCT07199764
• Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy · NCT06747845
• Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response · NCT06175000
• Marginal zone lymphoma: nemtabrutinib and rituximab · NCT07583810
• MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab · NCT07024706
• MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA) · NCT06150417
• Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance · NCT06483100
• Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma · NCT07291297
• Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms · NCT07693452
• Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome · NCT01624805
• Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN · NCT07710534
• Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors · NCT07671534
• Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease · NCT06627751
• Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome · NCT04256018
• Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer · NCT06361940
• Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma · NCT05535166
• Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma · NCT07163273
• Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma · NCT06453044
• Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma · NCT06594939
• Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma · NCT04792502
• MRI-based Focal Intraprostatic Simultaneous Integrated Boost (SIB) Intensification With De-escalated Adaptive-risk SBRT for Patients With Low to Intermediate Risk Prostate Cancer · NCT07644598
• MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma · NCT06377540
• Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma · NCT02605421
• NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial · NCT06821997
• NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial · NCT06450041
• Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma · NCT05489887
• Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · NCT07194980
• Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype · NCT06863402
• Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma · NCT07557056
• Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma · NCT07673367
• Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer · NCT05061550
• Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3 · NCT07595874
• Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features · NCT06449313
• Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma · NCT05825066
• Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer · NCT05132504
• Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients · NCT06353997
• Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus · NCT05319015
• Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers · NCT05919108
• Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer · NCT07808151
• Neoadjuvant Tebentafusp for Uveal Melanoma · NCT06414590
• Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis · NCT06794229
• NeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB-IV (M1a) Melanoma · NCT07740941
• Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro · NCT05952453
• Nirogacestat in Patients With Kaposi Sarcoma · NCT07539454
• Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas · NCT03258567
• Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma · NCT04594187
• Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL · NCT02393157
• Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T · NCT06784726
• Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer · NCT04090567
• Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax · NCT07471841
• Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent · NCT07304011
• Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma · NCT05296070
• Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer · NCT06369259
• Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer · NCT07216248
• Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique · NCT05045950
• Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma · NCT06044311
• Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers · NCT04410796
• Osimertinib and Cyclosporine A to Enhance Antitumor Efficacy in NSCLC · NCT07874490
• Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma · NCT04150640
• Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors · NCT07226713
• Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia · NCT07033598
• Palbociclib and Pembrolizumab In Central Nervous System Metastases · NCT02896335
• Pancreatic cancer: choose preoperative chemotherapy by SMAD4 status · NCT07748611
• Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL · NCT04906096
• pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer · NCT05799144
• PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC · NCT06239220
• PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma · NCT05286814
• Pembro With Radiation With or Without Olaparib · NCT05568550
• Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma · NCT06161545
• Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer · NCT05775471
• Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma · NCT04318717
• Pembrolizumab and Lenvatinib in Advanced Cervical Cancer · NCT04865887
• Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line Immunotherapy Maintenance · NCT07594015
• Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma · NCT07082439
• Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer · NCT05231122
• Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment · NCT07275216
• Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer · NCT05766371
• Pembrolizumab, Olaparib, and Temozolomide for People With Glioma · NCT05188508
• Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors · NCT06630416
• PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma · NCT05096481
• Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial · NCT07121595
• Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma · NCT06745076
• PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC · NCT06245889
• Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B) · NCT07795749
• Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates · NCT07292298
• Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL) · NCT07053059
• Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma · NCT06053658
• Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation · NCT06043674
• Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD · NCT07566364
• Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) · NCT06589440
• Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC · NCT06567743
• Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma · NCT06045247
• Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma · NCT07316010
• Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma · NCT06108232
• Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma · NCT07283731
• Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS · NCT07076186
• Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer · NCT01766297
• Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. · NCT06236724
• Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase · NCT07269470
• Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia · NCT06629584
• Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL · NCT07551583
• Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer · NCT05583708
• Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer · NCT07057791
• Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma · NCT03618550
• Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer · NCT04107077
• Phase II Trial Comparison of 3 vs 4 Fractions (BRACHY-FIT). · NCT07022470
• Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma · NCT05155033
• Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer · NCT07017673
• Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma · NCT06940518
• Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer · NCT06223568
• Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER) · NCT07313241
• Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I) · NCT07162480
• Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers · NCT05884320
• Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma · NCT07438626
• Pilot Study of Ivonescimab in Advanced/Metastatic Cutaneous Angiosarcoma · NCT07655570
• Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy. · NCT06218602
• Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia · NCT07685717
• Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma · NCT05344833
• Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients · NCT05776979
• Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma · NCT06254911
• Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma. · NCT07439172
• Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma · NCT06207799
• Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial · NCT06444269
• Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC · NCT05726370
• Preoperative Radiotherapy and Immunotherapy for Sinonasal and Anorectal Mucosal Melanoma · NCT05546827
• Propranolol With Chemotherapy or Chemoradiation for Esophageal Adenocarcinoma · NCT04682158
• PRORAD-5 PROstate RADiation in 5 Fractions: Phase II Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer. · NCT06369246
• Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC · NCT06745882
• Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation · NCT05790213
• Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study · NCT04175431
• Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation · NCT04838041
• Proton Beam Radiation Therapy After Treatment for Resected N2 Non-Small Cell Lung Cancer · NCT06008730
• Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas · NCT02598349
• PROton Therapy for Post Surgical Treatment of GYNecologic Cancer · NCT05758688
• PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer · NCT06392295
• PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · NCT07234981
• PT-112 in Subjects With Thymoma and Thymic Carcinoma · NCT05104736
• PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer · NCT06906887
• Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery · NCT04774419
• Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X) · NCT06305715
• Radiation Therapy Approaches for People With Prostate Cancer · NCT07751159
• Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery · NCT02734537
• Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer · NCT06601296
• Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers · NCT04205968
• Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel · NCT04449549
• Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer · NCT03936478
• Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV) · NCT07308886
• RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer · NCT07735624
• Recurrent ovarian cancers after PARP maintenance: sacituzumab govitecan combination · NCT07504588
• Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial] · NCT07071961
• REGULUS: MRI-guided Adaptive SABR for Liver Cancers · NCT07223307
• Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers · NCT06906341
• Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma · NCT07259317
• Repeat Breast Conserving Surgery Followed by Daily Partial Breast Irradiation in Ipsilateral Breast · NCT06129747
• Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer · NCT05998135
• Resectable lung cancer: cemiplimab and fianlimab before surgery · NCT06918132
• REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE) · NCT05632809
• Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer · NCT05467891
• Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study · NCT04900623
• Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer · NCT07250477
• Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas · NCT06350318
• Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes · NCT07228624
• Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia · NCT05592015
• Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma · NCT07356245
• Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma · NCT06991101
• Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C... · NCT06161532
• Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer · NCT05951179
• Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease · NCT07703436
• Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias · NCT07447817
• Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE) · NCT06458036
• Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC · NCT06263543
• Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression · NCT04363164
• Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC) · NCT05931393
• sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE) · NCT05332002
• Short Course ADT for High Risk Low/Intermediate Risk ARTERA Prostate Cancer · NCT07801664
• Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer · NCT07076485
• Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers · NCT05239546
• Single FrAction Interstitial BreaSt BracHytherApy · NCT07654257
• SMARCA4/2 Inhibitor for POU2F3-Positive SCLC · NCT07551635
• SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial · NCT05222620
• Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS) · NCT05483010
• Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial · NCT06378866
• Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases · NCT04899908
• Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction · NCT07132190
• Strategic Endocrine Therapy and Targeted Radiotherapy for Prostate Cancer · NCT07364071
• Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment · NCT05890352
• Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC) · NCT06549465
• Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate Canc · NCT05534646
• Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma · NCT05789303
• Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases · NCT05588388
• Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer · NCT04606914
• Study of Cryoablation and Nirogacestat for Desmoid Tumor · NCT05949099
• Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas · NCT07546812
• Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer · NCT07527858
• Study of EV for Recurrent Endometrial Carcinoma · NCT07139977
• Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors · NCT04165772
• Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL) · NCT06144606
• Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors · NCT06835387
• Study of Olutasidenib and Temozolomide in HGG · NCT06161974
• Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma · NCT07282587
• Study of Oral MRT-2359 With Apalutamide in Prostate Cancer · NCT07745361
• Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) · NCT06797635
• Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer · NCT06493019
• Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma · NCT02974647
• Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII · NCT07326566
• Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients · NCT06284590
• Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer · NCT07288177
• Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP · NCT07354074
• Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer · NCT05168566
• Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer · NCT07427394
• Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse · NCT06827860
• Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) · NCT06780098
• Suprachoroidal Administration in Subjects With Metastases to the Choroid · NCT06643884
• Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study · NCT06039371
• Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL · NCT06526793
• SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · NCT07322341
• SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer · NCT05570825
• T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer · NCT02133196
• Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma · NCT07731789
• Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents · NCT05442216
• TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer · NCT02693535
• Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial) · NCT06116682
• Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer · NCT07423585
• Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma · NCT06070012
• Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial · NCT07605416
• Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM Trial · NCT05333458
• Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma · NCT05633615
• Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial) · NCT05554406
• Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma · NCT05112601
• Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer · NCT04981509
• Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change · NCT03191149
• Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer · NCT06900595
• Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) · NCT06577441
• Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer · NCT03606967
• Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer · NCT06029270
• Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma · NCT07281417
• Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer · NCT07195734
• Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma · NCT05647265
• Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial · NCT05327686
• Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia · NCT06317662
• Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial · NCT06770582
• Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial) · NCT06917911
• Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy · NCT07003295
• Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial · NCT07551596
• Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma · NCT04840602
• Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma · NCT06649812
• Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia · NCT07061951
• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · NCT03866382
• Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure · NCT07085728
• Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse · NCT06948084
• Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells · NCT05691465
• Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial · NCT07516366
• Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers · NCT05408845
• Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial) · NCT06126276
• Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma · NCT04671667
• Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer · NCT06980038
• The COSMYC Trial (COmbined Suppression of MYC) · NCT06922318
• The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation · NCT06843551
• The Minimalist Trial-2 · NCT06702033
• The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer · NCT06439693
• The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC) · NCT06789757
• The SUGAR Study; SBRT and Relugolix) for Prostate Cancer · NCT06111781
• Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma · NCT06533748
• Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma · NCT04852328
• To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer · NCT07368998
• TOP 2301: Neoadjuvant Chemo for NSCLC · NCT06385262
• Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome · NCT07582172
• Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer · NCT04643366
• Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer · NCT05388773
• Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial) · NCT07393555
• TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd · NCT06533826
• Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION) · NCT05475171
• Trial Comparing LATTICE Radiotherapy vs Moderately Dose-escalated Palliative Radiation for Patients With Metastases. · NCT07594431
• Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC · NCT07246863
• Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC · NCT07098988
• Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant · NCT06315309
• Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment · NCT06617858
• Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors · NCT05263050
• Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome · NCT07216443
• Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMD · NCT07694986
• Trial of Trastuzumab Deruxtecan in Previously Treated HER2 · NCT06750484
• Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection · NCT07383649
• Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy · NCT06569368
• Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery · NCT06450873
• UCSD Image-Guided Cognitive-Sparing Radiosurgery for Intracranial Lesions · NCT04343157
• Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST) · NCT06902311
• Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma · NCT07603375
• Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma · NCT06517017
• Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer · NCT06445114
• Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) · NCT06317649
• Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML · NCT06504459
• Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma · NCT07734038
• Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia · NCT03586609
• Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm · NCT04216524
• Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer · NCT05538091
• Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas · NCT02523014
• VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma · NCT07831369
• Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation · NCT07286292
• WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma · NCT05879250
• XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma · NCT06571734
• XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer · NCT06959641
• XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer · NCT06568562
• Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC · NCT06555133
• Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM · NCT06561347
• Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL · NCT06849713
• Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases · NCT07043608
• Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery · NCT06959511
• Zanzalintinib in Men With Aggressive Variant Prostate Cancer · NCT07218666
• Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs) · NCT06926634
• ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer · NCT05071937
• Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy · NCT06930352